GENERAL INFORMATION | |||
---|---|---|---|
Company name: | Greenlight Biosciences España, S.L. | ||
Address: | Carretera Nacional IV, KM 566, 41720 Los Palacios Y Villafranca , Spain | ||
Web: | https://www.greenlightbiosciences.com/ | ||
Company creation date: | 2022 | ||
Employees: | 133 | ||
Field of activity: | Veterinary | ||
Record last updated on: | 14/06/2024 | ||
CONTACT DETAILS | |||
Contact name: | |||
Tel: | |||
Email: | |||
COMPANY SECTOR | |||
(Bio)Pharmaceutical: | |||
Early manufacturing/Research&Discovery stage: | |||
Development stage: | |||
Commercialisation/Marketing stage (EU/Non-EU): | |||
Medical Device and Technology: | |||
Development stage: | |||
Commercialisation/Marketing stage (EU/Non-EU): | |||
PRODUCT INFORMATION | |||
Medicinal Products | |||
Vaccines: | |||
Therapeutic medicines: | |||
Diagnostic and imaging products: | |||
Combined medicinal products and devices: | |||
Product Development Stages | Number of Products |
||
Research/Discovery: | |||
Pharmaceutical development: | |||
Preclinical: | |||
Clinical exploratory: | |||
Clinical confirmatory: | |||
(Pre)registration (EU/Non-EU): | |||
Marketing (EU/Non-EU): | |||
SUBSTANCES | |||
Chemical entities | |||
Single entities | |||
Combinations of single entities | |||
Peptides (chemically synthesised) | |||
Biologically derived proteins and peptides | |||
Monoclonal antibodies | |||
Recombinant proteins | |||
Extracted proteins | |||
Nucleic Acids (chemically synthesised/biologically derived) | |||
RNA | |||
DNA | |||
Polymer (natural and synthetic - excluding peptides, proteins and nucleic acids) | |||
Homopolymers | |||
Copolymers | |||
Advanced therapy medicinal products | |||
Somatic cell therapy products | |||
Tissue engineered products | |||
Gene therapy products | |||
Radionuclides | |||
Allergens | |||
Polyclonal immunoglobulins | |||
Herbal derived complex substances | |||
Animal derived complex substances | |||
Other | |||
SPECIFIC CATEGORIES | |||
Artificial intelligence, big data, software as medical device, digital health/medicines | |||
Biodefense | |||
Biosimilars | |||
Excipients | |||
Foods (functional foods, nutraceuticals) | |||
Generics | |||
Genetically modified organisms (GMOs) | |||
Homeopathics | |||
Maximum residue limits (veterinary medicines) | |||
Medicines for tropical diseases | |||
MUMS (‘Minor Use/Minor species’)/Limited market (veterinary medicines) | |||
Nanotechnology (including e.g. microparticles, liposomes, microbeads) | |||
New formulations/delivery methods | |||
Orphan medicines | |||
OTC (over the counter)/non-prescription/self-medication | |||
Paediatric medicines | |||
Personalised/targeted products, biomarkers, pharmacogenomics, precision medicines, companion diagnostics | |||
Stem cells | |||
Transgenic technology | |||
Other | THERAPEUTIC AREA | ||
A Alimentary tract and metabolism | |||
B Blood and blood forming organs | |||
C Cardiovascular system | |||
D Dermatologicals | |||
G Genito-urinary system and sex hormones | |||
H Systemic hormonal preparations, excluding sex hormones | |||
J General anti-infectives for systemic use | |||
L Anti-neoplastic and immunomodulating agents | |||
M Musculo-skeletal system | |||
N Nervous system | |||
P Anti-parasitic products, Insecticides, Repellents | |||
R Respiratory system | |||
S Sensory organs | |||
V Various | |||
Back to list |